Published in JAMA Neurol on March 01, 2014
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64
Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology (2015) 2.07
MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology (2015) 1.74
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci (2015) 1.53
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm (2015) 1.49
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2014) 1.29
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm (2015) 1.28
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol (2015) 1.23
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 1.15
Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol (2015) 1.10
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm (2015) 1.09
Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol (2014) 1.08
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation (2015) 1.05
Features of neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol (2014) 1.05
Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm (2015) 1.04
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation (2016) 1.01
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation (2016) 1.01
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun (2014) 1.01
Astrogliosis. Cold Spring Harb Perspect Biol (2014) 0.97
MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology (2016) 0.88
MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm (2014) 0.85
B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.85
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol (2015) 0.84
B Cells and Autoantibodies in Multiple Sclerosis. Int J Mol Sci (2015) 0.83
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83
Clinical and MRI phenotype of children with MOG antibodies. Mult Scler (2015) 0.82
Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. BMC Neurol (2014) 0.80
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation (2016) 0.80
Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol (2016) 0.79
Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathol (2016) 0.79
Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Chin Med J (Engl) (2016) 0.79
A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies. Neurol Neuroimmunol Neuroinflamm (2015) 0.78
MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm (2017) 0.78
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci (2016) 0.76
CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol (2014) 0.76
Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. J Neurol (2015) 0.75
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol (2016) 0.75
Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuroophthalmology (2015) 0.75
The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis. Mult Scler Int (2017) 0.75
Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply. JAMA Neurol (2014) 0.75
Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. Curr Neurol Neurosci Rep (2016) 0.75
MOG-IgG in neuromyelitis optica. J Neurol (2014) 0.75
Does aquaporin-4-seronegative neuromyelitis optica exist? JAMA Neurol (2014) 0.75
The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol (2016) 0.75
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology (2015) 0.75
Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
Commentary. J Neurosci Rural Pract (2017) 0.75
Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75
Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases. Int J Clin Exp Pathol (2015) 0.75
Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol (2017) 0.75
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci (2017) 0.75
Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity - The Expanding Spectrum of Neuromyelitis Optica. J Clin Diagn Res (2017) 0.75
The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination. Brain Sci (2017) 0.75
Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy. J Neuroophthalmol (2017) 0.75
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol (2016) 0.75
What's new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol (2017) 0.75